Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Terumo Corporation
  6. Summary
    4543   JP3546800008

TERUMO CORPORATION

(4543)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
4473 4476 4495 4589 4585 Last
3892800 3115400 1498000 2398400 1542700 Volume
+2.99% +0.07% +0.42% +2.09% -0.09% Change
Financials
Sales 2021 608 B 5 491 M 5 491 M
Net income 2021 75 952 M 686 M 686 M
Net Debt 2021 71 221 M 643 M 643 M
P/E ratio 2021 45,4x
Yield 2021 0,62%
Sales 2022 674 B 6 088 M 6 088 M
Net income 2022 89 649 M 810 M 810 M
Net Debt 2022 29 134 M 263 M 263 M
P/E ratio 2022 38,7x
Yield 2022 0,67%
Capitalization 3 464 B 31 510 M 31 292 M
EV / Sales 2021 5,82x
EV / Sales 2022 5,18x
Nbr of Employees 26 438
Free-Float 95,8%
More Financials
Company
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows: - cardiac surgery devices (55.7%); - medical products for hospitals (27.2%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.; - sanguine transfusion equipments... 
More about the company
Ratings of Terumo Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about TERUMO CORPORATION
05/13TERUMO  : Donates Additional USD 1 Million to Support the COVID-19 Solidarity Re..
AQ
05/13Nikkei slumps to 4-month low as inflation scare hits expensive shares
RE
05/12Nikkei slumps to 4-month low as inflation scare hits expensive shares
RE
04/14TERUMO  : Corporate Governance Report
PU
04/12TERUMO  : is building a Global Therapeutic Interventional Oncology team to offer..
AQ
03/30TERUMO CORPORATION : Ex-dividend day for final dividend
FA
03/11Japanese shares end higher as cyclicals rally; heavyweights' decline caps gai..
RE
03/10Japanese shares gain on cyclicals boost, selling in some heavyweights weighs
RE
03/10Japanese shares end nearly flat as year-end selloff by funds erases tech gain..
RE
03/09Japanese shares nearly flat as tech gains offset year-end selloff by funds
RE
03/09MARKET CHATTER : Japan's Terumo Develops Specialty Syringe to Draw Seven Doses F..
MT
03/08TERUMO  : Japan's Terumo says makes syringe to draw 7 doses from Pfizer vaccine ..
RE
02/15Syringe shortage hampers Japan's COVID-19 vaccination roll out
RE
02/07TERUMO  : A Novel Drug-Device Combination Product Using Terumo's Automated Injec..
AQ
01/03NOVARTIS  : In Canada, shippers race to move cancer treatments as COVID-19 groun..
RE
More news
News in other languages on TERUMO CORPORATION
05/11MÄRKTE ASIEN/Talfahrt bei Technologiewerten - Inflationssorgen belasten
03/10PLANETA BOLSA : La revista de prensa del miércoles 10 de marzo 2021
03/10PLANÈTE BOURSE  : La revue de presse du mercredi 10 mars 2021
02/15Coronavirus/Japon-Une pénurie de seringue ralentit la vaccination
2020Borsa Tokyo, Nikkei a massimo 6 mesi, bene titoli chip
More news
Chart TERUMO CORPORATION
Duration : Period :
Terumo Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TERUMO CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 4 871,43 JPY
Last Close Price 4 585,00 JPY
Spread / Highest target 17,8%
Spread / Average Target 6,25%
Spread / Lowest Target -8,40%
EPS Revisions
Managers and Directors
NameTitle
Shinjiro Sato President, CEO & Representative Director
Naoki Muto Chief Financial & Accounting Officer
Takayoshi Mimura Chairman
Katsuya Takeuchi Chief Information Officer & Executive Officer
Kazuhisa Senshu Chief Clinical & Regulatory Affairs Officer
Sector and Competitors
1st jan.Capitalization (M$)
TERUMO CORPORATION6.33%31 510
ABBOTT LABORATORIES0.52%196 179
MEDTRONIC PLC6.73%168 525
BECTON, DICKINSON AND COMPANY-3.97%70 215
HOYA CORPORATION1.23%47 614
ALIGN TECHNOLOGY, INC.12.20%47 481